Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Liabilities and Shareholders Equity (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $185.0 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 38.01% to $185.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $914.2 million through Dec 2025, down 35.17% year-over-year, with the annual reading at $185.0 million for FY2025, 38.01% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $185.0 million at Lexicon Pharmaceuticals, down from $205.9 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $417.2 million in Q1 2024, with the low at $162.7 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 3 years is $275.8 million, with a median of $287.1 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity surged 156.41% in 2024, then crashed 39.58% in 2025.
  • Over 3 years, Liabilities and Shareholders Equity stood at $229.4 million in 2023, then surged by 30.07% to $298.4 million in 2024, then crashed by 38.01% to $185.0 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $185.0 million, $205.9 million, and $225.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.